Wolfe Research analyst Nigel Coe downgrades AMETEK (NYSE:AME) from Outperform to Peer Perform.
Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell Medicine To Further Evaluate Synergy Between Antibody Drug Conjugates And (Z)-Endoxifen
Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and
